AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22577905
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in non-obese group (BMI <27.5 kg/m(2))
Trial: 20795382
Drug: Bubo-M vaccine
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bubo-M vaccine
Trial: 20795382
Drug: Bubo-M vaccine
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bubo-M vaccine and hepatitis B vaccine
Trial: 16238909
Drug: Lopinavir 400
RxNorm normalized name: LOPINAVIR 400MG/RITONAVIR 100MG/5ML SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir 400 mg boosted with ritonavir 100 mg twice daily
Trial: 29792081
Drug: Researcher-developed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Researcher-developed treatment (small-group tutoring for 30 to 45 minutes for an average of 68 lessons, mean hours of instruction = 44.4, SD = 11.2)
Trial: 22878802
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents
Trial: 17532398
Drug: Adenosine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (1.5 mg/kg)
Trial: 15466673
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (200 mg intramuscular) every 2 weeks for 1 month
Trial: 15466673
Drug: Lupron (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupron (7.5 mg intramuscularly) every 4 weeks for 3 months
Trial: 7910724
Drug: Ketoconazole +
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole + Sucralfate (1.0 g) administered simultaneously with 240 ml of water
Trial: 7910724
Drug: Ketoconazole administered
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole administered 2 hours after Sucralfate (1.0 g)
Trial: 7910724
Drug: Ketoconazole administered
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole administered with 240 ml of water
Trial: 3582724
Drug: 1% hydrocortisone/10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% hydrocortisone/10% urea cream
Trial: 23078631
Drug: Idrabiotaparinux (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrabiotaparinux (3.0 mg)
Trial: 16934051
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg daily for 4 days
Trial: 10776362
Drug: Step Test
RxNorm normalized name: SureStep Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step Test Exercise Prescription (STEP)
Trial: 10776362
Drug: Counseling using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling using the American College of Sports Medicine guidelines (control)
Trial: 9176463
Drug: Discontinuous-long protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuous-long protocol (n = 68) with GnRH agonist administered from luteal phase until cycle day 7, followed by pure FSH administration.
Trial: 9176463
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol (n = 69) with GnRH agonist administered until the day before hCG administration.
Trial: 1363221
Drug: F2/E2 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F2/E2 group (fentanyl 2 micrograms.kg‐1 and esmolol 2 mg.kg‐1)
Trial: 1363221
Drug: E2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 group (esmolol 2 mg.kg‐1)
Trial: 30804464
Drug: Chlorthalidone-based stepped
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone-based stepped care therapy
Trial: 30003628
Drug: Norwegian psychomotor
RxNorm normalized name: Norwegian Angelica
DrugBank: Angelica archangelica root (DB14283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norwegian psychomotor physiotherapy (NPMP) once weekly for 6 months
Trial: 23357150
Drug: Weekly lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly lipid apheresis by cascade plasma filtration (CPF) plus atorvastatin
Trial: 23357150
Drug: Atorvastatin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin alone (control group)
Trial: 23357150
Drug: Weekly lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly lipid apheresis by cascade plasma filtration (CPF)
Trial: 19874992
Drug: High-dose modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose modified-release nicotinic acid (2 g daily)
Trial: 18210887
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (hepatectomy plus radiofrequency ablation and 125I implantation)
Trial: 14648180
Drug: Bromocriptin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptin (7.5 mg) combined with clomiphene citrate (150 mg on days 5-9)
Trial: 14648180
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with clomiphene citrate (150 mg on days 5-9)
Trial: 14648180
Drug: Bromocriptin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptin (7.5 mg)
Trial: 8165811
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg t.i.d. orally for 3 months in addition to oral litholysis (OLL) with ursodeoxycholic acid 500 mg/day and chenodeoxycholic acid 500 mg/day
Trial: 8165811
Drug: Oral litholysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral litholysis (OLL) only
Trial: 28177671
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for 7 days
Trial: 23286756
Drug: α‐tocopherol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐tocopherol supplementation (50 mg/day)
Trial: 23286756
Drug: β‐carotene supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐carotene supplementation (20 mg/day)
Trial: 18421801
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg s.c. scopolamine
Trial: 18421801
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg s.c. scopolamine
Trial: 18421801
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg s.c. scopolamine
Trial: 12679702
Drug: Universal nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Universal nevirapine (NVP) therapy
Trial: 12679702
Drug: Targeted nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted nevirapine (NVP) therapy
Trial: 10857891
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic prophylaxis during cisplatin chemotherapy
Trial: 7479228
Drug: i.v. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. injection of heparin
Trial: 27383814
Drug: Antibiotic Prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic Prophylaxis (AP+)
Trial: 24158898
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential regimen (40 mg of pantoprazole, 1 g of amoxicillin for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Trial: 24158898
Drug: Standard 14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 14-day therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily)
Trial: 24158898
Drug: Standard 14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 14-day therapy
Trial: 21424566
Drug: Conventional bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional bowel preparation (full cathartic dose and oral contrast medium for 3 days prior to study)
Trial: 21424566
Drug: Reduced bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced bowel preparation (oral contrast medium administered only on the day of investigation)
Trial: 14644714
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable hydrogels
Trial: 11004031
Drug: Perflubron emulsion
RxNorm normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perflubron emulsion IV (1.2 g PFC/kg)
Trial: 11004031
Drug: Perflubron emulsion
RxNorm normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perflubron emulsion IV (1.8 g PFC/kg)
Trial: 11004031
Drug: Saline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (3 mL/kg) control
Trial: 8400072
Drug: Pharmacist-assisted dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-assisted dosing (Group 2)
Trial: 8400072
Drug: Pharmacist-directed dosing
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-directed dosing (Group 3)
Trial: 8400072
Drug: Usual physician‐directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual physician‐directed dosing (Group 1)
Trial: 3536490
Drug: Labetalol at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol at a dose of 0.8 mg kg‐1 (Group II)
Trial: 29537453
Drug: Topical Tavaborole
RxNorm normalized name: tavaborole Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Tavaborole
Trial: 22305462
Drug: Aspirin (81‐324
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81‐324 mg per day)
Trial: 15781736
Drug: Nesiritide (FDA-approved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (FDA-approved doses < or =0.03 microg x kg(‐1) x min(‐1))
Trial: 15781736
Drug: Nesiritide (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (any dose up to 0.06 microg x kg(‐1) x min(‐1))
Trial: 15781736
Drug: Low-dose nesiritide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nesiritide (< or =0.015 microg x kg(‐1) x min(‐1))
Trial: 15781736
Drug: Nesiritide (FDA-approved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (FDA-approved doses)
Trial: 15781736
Drug: Any control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any control therapy (including non-inotrope- and inotrope-based therapies)
Trial: 1800105
Drug: Four units
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four units of alcohol (95 ml of 40% spirit)
Trial: 6479183
Drug: Dihydralazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (25 mg i.v.)
Trial: 6479183
Drug: Dihydralazine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (100 mg oral)
Trial: 6479183
Drug: Dihydralazine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (20 mg day‐1 oral)
Trial: 31485809
Drug: Pre-incisional nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-incisional nefopam (20 mg before skin incision)
Trial: 31485809
Drug: Post-incisional nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-incisional nefopam (20 mg at 1 h after incision)
Trial: 29419934
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (NM) at 0.5 mg/kg/h during IHD for 5 hours
Trial: 29419934
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (NM) at 0.25 mg/kg/h during IHD
Trial: 29419934
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) during IHD
Trial: 24309219
Drug: Oral ibuprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen, 800 mg given 60-90 min preprocedure
Trial: 24309219
Drug: Intramuscular ketorolac,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac, 60 mg given 30-60 min preprocedure
Trial: 19765954
Drug: L-glutamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine (0.5 g kg(‐1) d(‐1))
Trial: 18380208
Drug: Hydrocortisone butyrate
RxNorm normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyrate 0.1% lotion
Trial: 16079640
Drug: Pravastatin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin, 40 mg daily
Trial: 7670782
Drug: GTN patches
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN patches (0.2 mg/h)
Trial: 3103163
Drug: Aniracetam 1
RxNorm normalized name: aniracetam
DrugBank: Aniracetam (DB04599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aniracetam 1 g daily for 3 months
Trial: 28587649
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) plus standardised medical care (SMC)
Trial: 23522532
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration of 1.8 mL 4% articaine hydrochloride with 1:100,000 adrenaline at the canine and first molar
Trial: 23522532
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration at the second molar
Trial: 23522532
Drug: Injections at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections at adjacent sites (canine and first molar)
Trial: 23522532
Drug: Injections at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections at different sites of the mandible
Trial: 11413894
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy (specific drugs not mentioned)
Trial: 2725119
Drug: Nicotine dose
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine dose adapted to daily cigarette consumption (n = 51)
Trial: 2725119
Drug: Standardized nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized nicotine dose (n = 49)
Trial: 29151484
Drug: Glucosamine (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine (3000 mg/day for 4 weeks)
Trial: 18022173
Drug: Folate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate (0.5 mg/day)
Trial: 11840583
Drug: oral midazolam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral midazolam, 0.2 mg/kg as anesthetic premedication
Trial: 11840583
Drug: saline (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline (oral normal saline as premedication)
Trial: 9512243
Drug: Earle's balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earle's balanced salt solution (control)
Trial: 2847567
Drug: 0.75 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml/kg of ethanol
Trial: 2847567
Drug: 1.1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 ml/kg of ethanol
Trial: 29405274
Drug: Gemcitabine chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine chemotherapy (1000 mg/m2, administered on days 1, 8, and 15 every 4 weeks for six cycles)
Trial: 29405274
Drug: Gemcitabine chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine chemotherapy
Trial: 25062592
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy for individuals at clinical high risk (FFT-CHR), 18 sessions over 6 months
Trial: 25062592
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy for individuals at clinical high risk (FFT-CHR)
Trial: 20547106
Drug: Adjunctive levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adjunctive levetiracetam (LEV) 20‐60mg/kg/day
Trial: 18993165
Drug: L-Carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine (2 g/day)
Trial: 16076146
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g raw purple carrots (463 micromol of anthocyanins: 400 micromol acylated, 63 micromol nonacylated)
Trial: 16076146
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g cooked purple carrots (357 micromol of anthocyanins: 308.5 micromol acylated, 48.5 micromol nonacylated)
Trial: 16076146
Drug: 500 g
RxNorm normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g cooked purple carrots (714 micromol of anthocyanins: 617 micromol acylated, 97 micromol nonacylated)
Trial: 7432323
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of immunoglobulins (Ig)
Trial: 9665110
Drug: Beta-carotene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (50 mg on alternate days for an average of 12 years)
Trial: 2503432
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 20 mg or more, oral administration three or four times a day
Trial: 2503432
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) during maintenance therapy
Trial: 22009509
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) followed by buccal misoprostol (800 µg)
Trial: 22009509
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol (800 µg only)
Trial: 7820333
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day for 7 days
Trial: 7820333
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg after omeprazole treatment
Trial: 7820333
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg before omeprazole treatment
Trial: 28212163
Drug: Concurrent multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent multiple organ dysfunction syndrome (MODS)
Trial: 25913848
Drug: High MUFA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High MUFA shake (95 g)
Trial: 25913848
Drug: High SFA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High SFA shake (95 g)
Trial: 23680708
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy with concomitant probiotic (Bifidus infantis)
Trial: 23680708
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy with pre-treatment of probiotic (Bifidus infantis for 2 weeks)
Trial: 23680708
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with concomitant probiotic (Bifidus infantis)
Trial: 23680708
Drug: Traditional standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional standard triple therapy (control group)
Trial: 21305611
Drug: Nicotine-containing lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-containing lozenge (NL)
Trial: 17162243
Drug: Serum insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum insulin
Trial: 31818152
Drug: Acetaminophen (APAP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP), 4 grams daily for two weeks
Trial: 31818152
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) with 20 mL propylene glycol (PG), 4 grams daily for two weeks
Trial: 23343395
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine trial (RV 144 prime-boost)
Trial: 9411464
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment with antidepressants
Trial: 9411464
Drug: Psychological and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological and pharmacological treatments
Trial: 8160789
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of endothelin-1 (ET-1) at a rate of 1 pmol.min-1.kg-1 for 60 min